WO2009095499A1 - Verwendung von amidoximcarbonsäureesters und n-hydroxyguanidincarbonsäureesters zur herstellung von prodrugs - Google Patents
Verwendung von amidoximcarbonsäureesters und n-hydroxyguanidincarbonsäureesters zur herstellung von prodrugs Download PDFInfo
- Publication number
- WO2009095499A1 WO2009095499A1 PCT/EP2009/051132 EP2009051132W WO2009095499A1 WO 2009095499 A1 WO2009095499 A1 WO 2009095499A1 EP 2009051132 W EP2009051132 W EP 2009051132W WO 2009095499 A1 WO2009095499 A1 WO 2009095499A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inhibitor
- blood
- acid esters
- carboxylic acid
- amidoxime
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/32—Oximes
- C07C251/62—Oximes having oxygen atoms of oxyimino groups esterified
- C07C251/64—Oximes having oxygen atoms of oxyimino groups esterified by carboxylic acids
- C07C251/66—Oximes having oxygen atoms of oxyimino groups esterified by carboxylic acids with the esterifying carboxyl groups bound to hydrogen atoms, to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a use of an amidoximcarboxylic acid ester in a method for improving the bioavailability and permitting the blood-permeability of drugs which comprise at least one or more amidm, guasidm, N-hydroxyamidine (amidoxime) or N-hydroxyguanidine Have functions and correspondingly modified Aizneistoffe containing drugs.
- Pharmaceutical preparations containing an active substance with one or more amidine or guanidine functions show almost no pharmacological action when administered orally.
- the prerequisite for a therapeutic effect of an active substance after oral administration is its absorption from the gastrointestinal tract.
- the most important mechanism of such an effect is passive diffusion.
- the degree of absorption on the path of passive diffusion depends on the lipophilicity and thus also on the acidity and the basicity of the active substance.
- the Blood-Him barrier provides an effective barrier to the absorption of substances into the brain. It ensures selective uptake and prevents the ingress of substances.
- the blood-brain barrier functions not only as a physical, but also as an enzymatic barrier.
- Various processes are involved in the penetration of substances into the brain In comparison to other indications, there are only a few drugs on the market that have an effect on the central nervous system (CNS). The majority of these pass through diffusion into the CNS.
- Transporters, peptide transporters and amino acid transporters expressed at the blood-brain barrier [TAMAI, L; TSUJI, A.J Pharm. 2000, 89, 1371-1388 AND DESOER, A .; V AN DER
- SANDT 5 1. Annu Rev Pharmacol Toxicol 2003, 43, 629-656]. Larger molecules, such as insulin or iron-containing transferrin, are taken up via the receptor-mediated transport. Especially the insulin and the transferrin receptor play a big role
- the amirosic acid L-dopa has been used as a prodrug principle so that the water-soluble catecholamine dopamine can cross the blood-brain barrier.
- the transport is done by the amino acid
- Transporter LATl large neutral amino acid transporter
- Diamidines are used as antiparasitic agents against malaria, against Pneumocystis jiroveci (formerly carinii) pneumonia, against trypanosomiasis (African sleeping sickness) and against leishmaniasis [WERBOVETZ, KL Curr Opin ⁇ ves ⁇ g Drugs 2006, 7, 147-157]: Especially in developing countries These diseases represent a major problem with high mortality rates.
- Pentamidine Pulcose ®
- Pentamidine has been used in the early stages of African sleeping sickness for 60 years.
- the meningoencephalitic stage there is no longer any efficacy because the blood-brain barrier can not be successfully passed. It must therefore be given very toxic arsenic compounds.
- N " -hydroxylated derivatives such as the amidoximes and the ⁇ -hydroxyguanidines, show less basicity by the introduction of the oxygen atom and are not protonated under physiological conditions
- Benzamidoxime is a model compound for many drugs containing an amidoxime function [Clement, B. Drug Met Rev 2002, 34, 565-579].
- Pentamidine and diminazene are diamidines and are not absorbed after oral administration. Therefore, they were converted into amidoxime prodrugs (DE 102006 034 256.9).
- pentamidine shows that the conversion into the pentoxime ester is accompanied by a reduction in solubility. This is probably also the reason for the less than 100% bioavailability of pentamidine following oral administration of the pentoxide ester [Clement B .; Bürenheide A .; Rieckert W .; Black J. ChemMedChem 2006, 1, 1260-7].
- n O-12 and Rj is hydrogen or an alkyl or an aryl radical, or their salts as a substitute for one or more amidino, N-hydroxyamidine (A ⁇ ddoxim), guanidine or N-hydroxyguanidine functions of a To use drug in medicaments to improve the solubility, bioavailability and Blut-Him-Schranken Oberkeit of the drug.
- n is chosen greater than 12, an improvement in the solubility, bioavailability and blood-brain barrier mobility is no longer possible.
- N-hydroxyamidines (amidoximes) and N-hydroxyguanidines are successful prodrug principles for increasing the oral bioavailability of amidines (DE 10 2006 034256.9).
- the inventively proposed esterification of amidoximes or N-hydroxyguanidines with with dicarboxylic acids and esters of dicarboxylic acids significantly improves the solubility, in particular the solubility in aqueous media and the Bioverfagée compared to the known prodrugs.
- the esterification of amidoximes or N-hydroxyguanidines with dicarboxylic acids / Dicarbonklareeste ⁇ i represents due to the introduced negative charge of the deprotonated acid function is a reversal of the charges compared to benzamidine, thus increased bioavailability and solubility in aqueous media is effected
- the particular advantage of the compounds according to the invention is that they are deprotonated in the blood and thus as substrate for the transporter for organic Anion ⁇ n
- African sleep sickness as the second phase of the disease can be treated effectively.
- this esterification should allow overcoming the blood-Hrm barrier.
- the compound In the blood, the compound will be deprotonated so that it could be a substrate for the organic anion transporter (OAT) at the blood-brain barrier.
- OAT organic anion transporter
- the substitution of at least one or more amidine, V-hydroxyamidine (ar ⁇ idoxime), guanidine and / V-hydroxyguanidine functional groups by the amidoxime dicarboxylic acid ester and the N-hydroxyguanidine dicarboxylic acid ester achieves the solubility of the drug in question is increased.
- the amidoxime dicarboxylic acid ester and the N-hydroxyguanidine dicarboxylic acid ester achieves the solubility of the drug in question is increased.
- the amidoxime dicarboxylic acid ester and the N-hydroxyguanidine dicarboxylic acid ester achieves the solubility of the drug in question is increased.
- the amidoxime dicarboxylic acid ester and the N-hydroxyguanidine dicarboxylic acid ester achieves the solubility of the drug in question is increased.
- the amidoxime dicarboxylic acid ester and the N-hydroxyguanidine dicarboxylic acid ester achieves the solubility of the drug in question
- the active substance contains at least one or more active amidine, N-hydroxyamidine (amidoxime), guanidine or N-hydroxyguanidine functions in the proposed form.
- the active ingredient may therefore be e.g. several Amidoxim- functions (eg two as in the Pentoximester) or N - Hydroxyguanidin-Funlctionen included, in which case at least one of these groups is modified in the manner described above Just as mixtures of active ingredients can be used, provided that at least one active ingredient or having several amidine, N-hydroxyamidine (amidoxiine), guanidine or N-hydroxyguanidine functions
- the oral dosage form may be presented as a liquid, semi-solid or solid preparation, in particular as a tablet, dragee, pellet or microcapsule.
- the active ingredient or the active ingredient mixture in a suitable non-toxic solvent such as water, monohydric alcohols, in particular emanols, polyhydric alcohols, in particular glycerol and / or PropandioL polyglycols, in particular Polyethylene glycols and / or miglyol, glycerol formal, dimethyl isosorbitol, natural or synthetic oils.
- a suitable non-toxic solvent such as water, monohydric alcohols, in particular emanols, polyhydric alcohols, in particular glycerol and / or PropandioL polyglycols, in particular Polyethylene glycols and / or miglyol, glycerol formal, dimethyl isosorbitol, natural or synthetic oils.
- the customary basic materials such as bentonite, veegum, guar gum and / or ceulose derivatives, in particular methyl cellulose and / or carboxymethyl cellulose, as well as polymers of vinyl alcohols and / or vinyl pyrrolidones, AlgLnate, pectins, polyacrylates, solid and / or liquid polyethylene glycols, paraffins, fatty alcohols, Vaseline and / or waxes, fatty acids and / or fatty acid esters for use.
- bentonite veegum, guar gum and / or ceulose derivatives, in particular methyl cellulose and / or carboxymethyl cellulose
- polymers of vinyl alcohols and / or vinyl pyrrolidones AlgLnate
- pectins polyacrylates
- solid and / or liquid polyethylene glycols paraffins
- fatty alcohols fatty alcohols
- Vaseline and / or waxes fatty acids and / or
- the per se known extenders such as, for example, colloidal silica, talc, lactose, starch powder, sugar, gelatin, metal oxides and / or metal salts, may be present in solid preparations.
- Other additives include stabilizers, emulsifiers, dispersants and preservatives.
- the medicaments modified according to the use according to the invention have an excellent absorbability and thus bioavailability when administered orally, as a result of which the pharmacological action of amidine or guanidine is markedly increased.
- an optimal dosage form for the oral administration of amidines can now be provided.
- Coagulation cascade Matriptase inhibitors
- anticoagulants thrombolytics
- Antifibrinolytic, DNA and RNA intercalating compounds such as pentamidine,
- Diminazene isometamidium
- N-methyl-D-aspartate receptor antagonists include N-methyl-D-aspartate receptor antagonists, and inhibitors of viral enzymes (such as neurai aiidase inhibitors).
- Active agents containing an effective amidine function or guanidia function can i.a. for the inhibition of blood coagulation, for the prophylaxis and therapy of visceral and cutaneous leishmaniasis, trypanosomiasis (Airican's sleeping sickness), Pneumocystis carinii pneumonia (PCP), growth inhibition of malignant tumors, blood pressure reduction, neuroprotection, as well as for the control of viral infections such as influenza and used by HIV infections.
- the invention basically comprises all active ingredients which have at least one amidine function or guanidine function, which has been converted according to the invention into an improved prodrug.
- the method according to the invention is thus applicable to a very broad range of classes of active ingredient and indications and can significantly increase the bioavailability of many drugs whose active form contains an amidine or a guanidine.
- compounds modified by the process according to the invention include the O-succinylbenzamidoxime 5 of the pentamidine succinic esters and the diyninazosuccinic acid esters
- the O-succinylbenzamidoxime is selected as model compounds for the new prodrug principles and administered orally to three rats.
- the metallization of the two esters to benzamidine proceeds in vivo as follows:
- Pentamidine succinic acid ester is shown in Figs. 2-3 in the appendix
- the animal experiment was approved by the Ministry of Agriculture, Environment and Rural Areas of Schleswig-Holstein on 04/07/2007
- the anesthesia is done by xylazine and ketamine. Both were injected in the.
- Siukonkatheter be implanted in the jugular vein and in the carotid artery. They have local antithrombotic and antiinflammatory properties but are not systemic. The eyes were treated during surgery with a comeaprotective ointment
- Animals Nutri plus ® an energy paste (soybean oil, molasses, cod liver oil, meat extract,
- the experimental animals are male Wistar rats with an average weight of 200 g.
- the animals are kept individually in cages. Every two days they receive concentrated feed. Water and dried food is available ad libitum.
- the animals are weighed in the evening before the substance application.
- the orally administered substances are administered via a gavage.
- the O-succinylbenzamine i doxime are dissolved in 100 mM phosphorous buffer pH 8.5.
- the intravenous benzamidine is dissolved in NaCl solution 0.9% to prevent hemolysis. After the injection is rinsed again with at least 0.5 ml of NaCl solution for 0 s 9%.
- the substance application takes place in the morning.
- the prodrugs are administered to three rats Benzamidine is administered intravenously to two rats
- the orally administered doses of O-succmylbenzarnidoxirns are 50 mg / kg body weight.
- Benzamidine was administered at a concentration of 10 mg / kg body weight REMOVAL OF BLOOD PRUNES
- the blood samples are collected over a period of eight hours after oral administration and six hours after intravenous administration. After oral administration, the samples are taken after 30, 60, 90, 120, 240 and 480 minutes, after intravenous administration after 5, 10, 20, 40, 80 and 360 minutes. Before the blood is drawn, the catheter is emptied by briefly aspirating until the appearance of blood. The blood collection
- Centrifugation be removed about 150 ul plasma as the supernatant, pipetted into Eppendorf tubes and frozen at -8O 0 C.
- Detector sensitivity Absorbance units fullscale: 2,000 Retention times: Benzamidoxime: 23.5 ⁇ 0.5 min
- the eluent was filtered with a Satorius membrane filter (0.45 ⁇ m) and degassed in an ultrasonic bath for 15 minutes
- Detector sensitivity Absorbance units fullscale: 2,000 Retention times: Benzamidine: 5.3 ⁇ 0.3 min
- the eluent was filtered with a Sartorius membrane filter (0.45 ⁇ m) and degassed in an ultrasonic bath for 15 minutes.
- Fig. 1 the plasma level curves of benzamidine after oral administration of the
- FIG. 2 shows the metabolism of Diminazensuccinylklareest ⁇ rs and Figure 3 shows the metabolism of Pentamidinsuccinylklareesters
- n is - 0, ..., 12 and Rl is selected from the group consisting of hydrogen, an alkyl radical and an aryl radical and their salts, as a substitute for one or more amidine, N-hydroxyamidine (amidoxime), guanidine or N-hydroxyguanidine functions of a drug in medicaments to improve the solubility, bioavailability and / or blood-brain barrier mobility of the drug.
- Rl is selected from the group consisting of hydrogen, an alkyl radical and an aryl radical and their salts, as a substitute for one or more amidine, N-hydroxyamidine (amidoxime), guanidine or N-hydroxyguanidine functions of a drug in medicaments to improve the solubility, bioavailability and / or blood-brain barrier mobility of the drug.
- the drug is selected from the group of Prot ⁇ as ⁇ hnmstoff ⁇ , the DNA and RNA intercalating compounds, the inhibitors of viral enzymes and the N-methyl-D-aspartate receptor antagonists.
- the protease inhibitor is a thrombin inhibitor, an inhibitor of factor Xa, factor VII or all proteases of the coagulation cascade or a Mataptasehernmstoff.
- the protease inhibitor is a urokinase inhibitor.
- the DNA- and RNA-intercalating compound is pentamidine, diminazene or isometamidium.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010544724A JP2011510956A (ja) | 2008-02-01 | 2009-02-02 | アミドキシムカルボン酸エステル及びn−ヒドロキシグアニジンカルボン酸エステルのプロドラッグの製造のための使用 |
CN200980103401.7A CN101951897B (zh) | 2008-02-01 | 2009-02-02 | 偕胺肟羧酸酯和n-羟胍羧酸酯用于制备前药的用途 |
SI200931253T SI2249821T1 (sl) | 2008-02-01 | 2009-02-02 | Uporaba estrov amidoksim karboksilne kisline in estrov n-hidroksigvanidin karboksilne kisline za izdelavo predzdravila |
EP09705303.7A EP2249821B1 (de) | 2008-02-01 | 2009-02-02 | Verwendung von amidoximcarbonsäureesters und n-hydroxyguanidincarbonsäureesters zur herstellung von prodrugs |
ES09705303.7T ES2547117T3 (es) | 2008-02-01 | 2009-02-02 | Utilización de ésteres de ácidos amidoxima-carboxílicos y de ésteres de ácidos N-hidroxiguanidino-carboxílicos para la preparación de profármacos |
AU2009209560A AU2009209560B2 (en) | 2008-02-01 | 2009-02-02 | Use of amidoxime carboxylic acid esters and N-hydroxyguanidine carboxylic acid esters for producing prodrugs |
PL09705303T PL2249821T3 (pl) | 2008-02-01 | 2009-02-02 | Zastosowanie estrów amidoksymowych kwasu karboksylowego i estrów nhydroksyguanidynowych kwasu karboksylowego do wytwarzania proleków |
CA2713784A CA2713784C (en) | 2008-02-01 | 2009-02-02 | Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs |
BRPI0906569-5A BRPI0906569A2 (pt) | 2008-02-01 | 2009-02-02 | Uso de ésteres de ácidos amidoximo-carboxílicos e de ésteres de ácidos n-hidroxiguanidino-carboxílicos para a produção de prodrogas |
DK09705303.7T DK2249821T3 (en) | 2008-02-01 | 2009-02-02 | Use of amidoximkarboxylsyreestre and N-hydroxyguanidin-karboxylsyreestre for the preparation of prodrugs |
ZA2010/04767A ZA201004767B (en) | 2008-02-01 | 2010-07-07 | Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs |
IL207286A IL207286A0 (en) | 2008-02-01 | 2010-07-29 | Use of amidoxime carboxylic acid esters and n - hydroxyguanidine carboxylic acid esters for producing prodrugs |
US12/847,415 US20110028756A1 (en) | 2008-02-01 | 2010-07-30 | Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs |
HK11107361.3A HK1153144A1 (zh) | 2008-02-01 | 2011-07-15 | 偕胺肟羧酸酯和 -羥胍羧酸酯用於製備前藥的用途 |
US14/455,272 US9353047B2 (en) | 2008-02-01 | 2014-08-08 | Method for producing prodrug from amidoxime and N-hydroxyguanidine carboxylic acid esters |
US14/581,384 US9662308B2 (en) | 2008-02-01 | 2014-12-23 | Orally bioavailable pentamidine prodrugs for the treatment of diseases |
HRP20150961TT HRP20150961T1 (hr) | 2008-02-01 | 2015-09-11 | Uporaba amidoksimskih estera karboksilne kiseline i n-hidroksigvanidinskih estera karboksilne kiseline za proizvodnju prolijeka |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008007381.4 | 2008-02-01 | ||
DE102008007381A DE102008007381A1 (de) | 2008-02-01 | 2008-02-01 | Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/554,536 Continuation US20130085180A1 (en) | 2008-02-01 | 2012-10-05 | Oral bioavailable pentamidin prodrugs for treatment of diseases |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/847,415 Continuation US20110028756A1 (en) | 2008-02-01 | 2010-07-30 | Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009095499A1 true WO2009095499A1 (de) | 2009-08-06 |
Family
ID=40532565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/051132 WO2009095499A1 (de) | 2008-02-01 | 2009-02-02 | Verwendung von amidoximcarbonsäureesters und n-hydroxyguanidincarbonsäureesters zur herstellung von prodrugs |
Country Status (21)
Country | Link |
---|---|
US (2) | US20110028756A1 (de) |
EP (3) | EP2249821B1 (de) |
JP (2) | JP2011510956A (de) |
KR (1) | KR20100110875A (de) |
CN (1) | CN101951897B (de) |
AU (1) | AU2009209560B2 (de) |
BR (1) | BRPI0906569A2 (de) |
CA (1) | CA2713784C (de) |
CY (1) | CY1116801T1 (de) |
DE (1) | DE102008007381A1 (de) |
DK (1) | DK2249821T3 (de) |
ES (1) | ES2547117T3 (de) |
HK (1) | HK1153144A1 (de) |
HR (1) | HRP20150961T1 (de) |
HU (1) | HUE026276T2 (de) |
IL (1) | IL207286A0 (de) |
PL (1) | PL2249821T3 (de) |
PT (1) | PT2249821E (de) |
SI (1) | SI2249821T1 (de) |
WO (1) | WO2009095499A1 (de) |
ZA (1) | ZA201004767B (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010078867A1 (de) * | 2009-01-09 | 2010-07-15 | Christian-Albrechts-Universität Zu Kiel | Verfahren zur verbesserten bioaktivierung von arzneistoffen |
EP2550966A1 (de) | 2011-07-25 | 2013-01-30 | Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG | Dabigatran-Amidoximsäureesters als Prodrugs und ihre Verwendung als Arzneimittel |
EP2550963A1 (de) | 2011-07-25 | 2013-01-30 | Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG | Pentamidin-Amidoximsäureesters als Prodrugs und ihre Verwendung als Arzneimittel |
EP2934501A4 (de) * | 2012-12-21 | 2016-06-01 | Verlyx Pharma Inc | Verwendungen und verfahren zur behandlung von lebererkrankungen oder -leiden |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9662308B2 (en) | 2008-02-01 | 2017-05-30 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Orally bioavailable pentamidine prodrugs for the treatment of diseases |
DE102008007381A1 (de) | 2008-02-01 | 2009-08-13 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg | Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten |
ES2416004B1 (es) * | 2012-01-24 | 2014-01-28 | Investigaciones Farmaceuticas Y Veterinarias, S.L. | Composición farmacéutica que comprende cloruro de isometamidium en solución para el tratamiento de la tripanosomiasis en animales. |
CN103420994B (zh) * | 2012-05-24 | 2016-04-06 | 天津药物研究院 | 作为前药的达比加群酯衍生物及其制备方法和用途 |
CN106831611B (zh) * | 2017-01-23 | 2019-06-21 | 北京化工大学 | 一种偕胺肟类化合物及其在制备抑制癌细胞增殖药的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5786383A (en) * | 1993-06-28 | 1998-07-28 | Clement; Bernd | Pharmaceutical preparation |
WO2008009264A1 (de) * | 2006-07-21 | 2008-01-24 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Verbesserung der bioverfügbarkeit von wirkstoffen mit amidinfunktion in arzneimitteln |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001031586A (ja) * | 1999-07-14 | 2001-02-06 | Sunstar Inc | 動脈硬化症及び動脈硬化症に起因する疾患の予防又は治療組成物 |
EP1294405A2 (de) | 2000-06-14 | 2003-03-26 | Corixa Corporation | Durch thimet oligopeptidase spaltbare prodrugs |
ATE504315T1 (de) * | 2001-06-11 | 2011-04-15 | Medarex Inc | Methode für die ausarbeitung von cd10-aktivierten prodrug-verbindungen |
EP1482940A2 (de) | 2001-10-03 | 2004-12-08 | Pharmacia Corporation | Prodrugs von substituierten polyzyclischen vebindungen für die selektive hemmung der koagulationskaskade |
DE10323898A1 (de) * | 2003-05-26 | 2004-12-23 | Wilex Ag | Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe |
CN100567267C (zh) * | 2004-06-30 | 2009-12-09 | 富山化学工业株式会社 | 芳脒衍生物、其盐、及含有这些的抗真菌剂 |
DE102008007381A1 (de) | 2008-02-01 | 2009-08-13 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg | Amidine und Guanidine und deren Derivate zur Behandlung von Krankheiten |
-
2008
- 2008-02-01 DE DE102008007381A patent/DE102008007381A1/de not_active Withdrawn
-
2009
- 2009-02-02 EP EP09705303.7A patent/EP2249821B1/de active Active
- 2009-02-02 SI SI200931253T patent/SI2249821T1/sl unknown
- 2009-02-02 PL PL09705303T patent/PL2249821T3/pl unknown
- 2009-02-02 ES ES09705303.7T patent/ES2547117T3/es active Active
- 2009-02-02 KR KR1020107018471A patent/KR20100110875A/ko not_active Application Discontinuation
- 2009-02-02 DK DK09705303.7T patent/DK2249821T3/en active
- 2009-02-02 CN CN200980103401.7A patent/CN101951897B/zh not_active Expired - Fee Related
- 2009-02-02 PT PT97053037T patent/PT2249821E/pt unknown
- 2009-02-02 WO PCT/EP2009/051132 patent/WO2009095499A1/de active Application Filing
- 2009-02-02 JP JP2010544724A patent/JP2011510956A/ja not_active Withdrawn
- 2009-02-02 BR BRPI0906569-5A patent/BRPI0906569A2/pt not_active IP Right Cessation
- 2009-02-02 EP EP20140155230 patent/EP2732816A1/de not_active Ceased
- 2009-02-02 AU AU2009209560A patent/AU2009209560B2/en not_active Ceased
- 2009-02-02 EP EP15178466.7A patent/EP2985021A1/de not_active Withdrawn
- 2009-02-02 CA CA2713784A patent/CA2713784C/en active Active
- 2009-02-02 HU HUE09705303A patent/HUE026276T2/en unknown
-
2010
- 2010-07-07 ZA ZA2010/04767A patent/ZA201004767B/en unknown
- 2010-07-29 IL IL207286A patent/IL207286A0/en unknown
- 2010-07-30 US US12/847,415 patent/US20110028756A1/en not_active Abandoned
-
2011
- 2011-07-15 HK HK11107361.3A patent/HK1153144A1/zh not_active IP Right Cessation
-
2014
- 2014-08-08 US US14/455,272 patent/US9353047B2/en active Active
-
2015
- 2015-09-11 HR HRP20150961TT patent/HRP20150961T1/hr unknown
- 2015-10-20 CY CY20151100936T patent/CY1116801T1/el unknown
-
2016
- 2016-06-14 JP JP2016117936A patent/JP2016193927A/ja active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5786383A (en) * | 1993-06-28 | 1998-07-28 | Clement; Bernd | Pharmaceutical preparation |
WO2008009264A1 (de) * | 2006-07-21 | 2008-01-24 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Verbesserung der bioverfügbarkeit von wirkstoffen mit amidinfunktion in arzneimitteln |
Non-Patent Citations (2)
Title |
---|
REEH CHRISTIANE ET AL: "N,N '-dihydroxyamidines: A new prodrug principle to improve the oral bioavailability of amidines", JOURNAL OF MEDICINAL CHEMISTRY, vol. 50, no. 26, December 2007 (2007-12-01), pages 6730 - 6734, XP002524112, ISSN: 0022-2623 * |
SRIDHAR VARADARAJAN: "PRODRUGS", INTERNET ARTICLE, Universidad of North Carolina Wilmington, pages 1 - 5, XP002524119, Retrieved from the Internet <URL:http://uncw.edu/chem/courses/varadarajan/chm417/Course%20Materials/Prodrugs.pdf> [retrieved on 20070419] * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010078867A1 (de) * | 2009-01-09 | 2010-07-15 | Christian-Albrechts-Universität Zu Kiel | Verfahren zur verbesserten bioaktivierung von arzneistoffen |
AU2010204395B2 (en) * | 2009-01-09 | 2016-04-14 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Method for improved bioactivation of medications |
EP2550966A1 (de) | 2011-07-25 | 2013-01-30 | Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG | Dabigatran-Amidoximsäureesters als Prodrugs und ihre Verwendung als Arzneimittel |
EP2550963A1 (de) | 2011-07-25 | 2013-01-30 | Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG | Pentamidin-Amidoximsäureesters als Prodrugs und ihre Verwendung als Arzneimittel |
WO2013013946A1 (de) | 2011-07-25 | 2013-01-31 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Dabigatran-amidoximsäureesters als prodrugs und ihre verwendung als arzneimittel |
WO2013014059A1 (de) | 2011-07-25 | 2013-01-31 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Pentamidin-amidoximsäureesters als prodrugs und ihre verwendung als arzneimittel |
US8853245B2 (en) | 2011-07-25 | 2014-10-07 | Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co. Kg | Orally bioavailable dabigatran prodrugs for the treatment of diseases |
EP2934501A4 (de) * | 2012-12-21 | 2016-06-01 | Verlyx Pharma Inc | Verwendungen und verfahren zur behandlung von lebererkrankungen oder -leiden |
US9375411B2 (en) | 2012-12-21 | 2016-06-28 | Verlyx Pharma Inc. | Uses and methods for the treatment of liver diseases or conditions |
Also Published As
Publication number | Publication date |
---|---|
PT2249821E (pt) | 2015-10-13 |
HUE026276T2 (en) | 2016-06-28 |
EP2732816A1 (de) | 2014-05-21 |
CY1116801T1 (el) | 2017-03-15 |
ES2547117T3 (es) | 2015-10-01 |
HK1153144A1 (zh) | 2012-03-23 |
PL2249821T3 (pl) | 2015-12-31 |
EP2985021A1 (de) | 2016-02-17 |
AU2009209560A1 (en) | 2009-08-06 |
US9353047B2 (en) | 2016-05-31 |
DK2249821T3 (en) | 2015-10-05 |
CN101951897A (zh) | 2011-01-19 |
BRPI0906569A2 (pt) | 2015-07-07 |
JP2011510956A (ja) | 2011-04-07 |
HRP20150961T1 (hr) | 2015-11-06 |
EP2249821A1 (de) | 2010-11-17 |
US20140350293A1 (en) | 2014-11-27 |
CN101951897B (zh) | 2016-01-20 |
EP2249821B1 (de) | 2015-07-29 |
IL207286A0 (en) | 2010-12-30 |
JP2016193927A (ja) | 2016-11-17 |
CA2713784A1 (en) | 2009-08-06 |
AU2009209560B2 (en) | 2013-10-31 |
US20110028756A1 (en) | 2011-02-03 |
DE102008007381A1 (de) | 2009-08-13 |
SI2249821T1 (sl) | 2015-12-31 |
CA2713784C (en) | 2016-09-27 |
KR20100110875A (ko) | 2010-10-13 |
ZA201004767B (en) | 2011-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2249821B1 (de) | Verwendung von amidoximcarbonsäureesters und n-hydroxyguanidincarbonsäureesters zur herstellung von prodrugs | |
DE69227512T2 (de) | N6-(hydrazinoiminomethyl)lysin und verfahren zur hemmung der stickstoffbildung im körper | |
DE602004007352T2 (de) | Hydroxamsäurederivate mit entzündungshemmender wirkung | |
EP2046732B1 (de) | Verbesserung der bioverfügbarkeit von wirkstoffen mit amidinfunktion in arzneimitteln | |
EP0276803B1 (de) | 1-(4-Hydroxy-3,5-di-tert.-butyl-benzoyl)-homopiperazin, verschiedene von dessen Derivaten, Verfahren zur Herstellung dieser Verbindungen, die sie enthaltenden Arzneimittel und ihre Verwendung | |
EP2848249A2 (de) | Aminosäurederivate als Arzneimittel | |
EP2376074A1 (de) | Verfahren zur verbesserten bioaktivierung von arzneistoffen | |
AU2014200451B2 (en) | Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs | |
KR20160027967A (ko) | 전구약물을 생성하기 위한 아미드옥심 카르복실산 에스테르류 및 엔-하이드록시구아니딘 카르복실산 에스테르류의 용도 | |
US3608080A (en) | Process for the treatment of hyperuremia of nephritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980103401.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09705303 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 207286 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2713784 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010544724 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009209560 Country of ref document: AU Ref document number: 2009705303 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20107018471 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5423/CHENP/2010 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2009209560 Country of ref document: AU Date of ref document: 20090202 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: PI0906569 Country of ref document: BR Kind code of ref document: A2 Effective date: 20100727 |